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ISSCR: Committee ForumEthical and Policy Issues in the Clinical
Translation of Stem Cells: Report of a Focus
Session at the ISSCR Tenth Annual MeetingAlongside the scientific barriers to the clinical translation of stem cell research are ethical and regulatory
hurdles. Some of these challenges described by the Ethics and Public Policy Committee at the ISSCR Tenth
Annual Meeting are presented here.The clinical translation of stem cells will be associated with an
array of scientific, ethical, and regulatory challenges, both ex-
pected and unexpected. While many of these issues were
addressed in the International Society for Stem Cell Research
(ISSCR)’s Guidelines for the Clinical Translation of Stem Cells
(ISSCR, 2008), others have emerged over time. The ISSCR
Ethics and Public Policy Committee organized a focus session
at the 2012 Annual Meeting to raise and discuss some of the
major issues to help ensure that the clinical translation of stem
cells will be safe and appropriate (Table 1). The session ad-
dressed both preclinical barriers to translation (preclinical data;
transfer and sharing of materials) and clinical barriers to human
trials (trial design and comparators; perception and communi-
cation of risk to patients, families, and patient groups). Each of
these topics was addressed by a concise structured talk, fol-
lowed by short, invited commentaries. In this report, we provide
a brief discussion of each topic and identify issues that warrant
further discussion.
Preclinical Data
Successful translation of stem cell research into clinical applica-
tions must rely on a sound biological foundation, which includes
high quality in vitro and in vivo preclinical data. The ISSCR’s
Guidelines for the Clinical Translation of Stem Cells describes
the importance of preclinical studies in relevant animal models
(ISSCR, 2008). While extensive in vivo preclinical work is con-
ducted with rodents, Jason Robert queried whether rodent
research is a sufficient foundation for the modeling of stem cell
biology and human disease. Rodents are convenient and
provide a tractable mammalian system for initial proof-of-prin-
ciple in vivo and permit preliminary studies of safety and toxicity
of prospective cell-based therapeutics. Moreover, because they
are experimentally tractable, scientists have both the liberty and
ability to perform research that is not possible in human beings.
Yet using rodents exclusively or predominantly presents a host
of conceptual, methodological, and ethical challenges for
achieving translational success in stem cell biology. While
work with them facilitates the research enterprise, it also fosters
a certain abstraction from the historical, evolutionary, ecological,
and developmental contingency of organisms in nonexperi-
mental conditions (Robert, 2008). Further, this research runs
the risk of blurring the lines between what we actually want to
know and what we are capable of discovering. For example,
while a rodent model might demonstrate success in the repair
of spinal cord injury, whether such success would be expected
in a human is unclear. Robert concluded with a call for researchusing a greater diversity of animal systems so as to justify
more reliable inferences to humans, despite potential accompa-
nying challenges such as those related to some types of exper-
imentation with other nonhuman animals. Thus, there is a need
for additional guidance on how these issues can be addressed
in practice so as to help ensure safe and appropriate clinical
translation.
Commentators described additional barriers to preclinical
research, in particular those related to using human cells lines.
These included limitations on the use of cell lines due to restric-
tions specified in the consent document for the collection of
biological materials used to create the lines; questions about
ownership of the lines (the scientist, the institution, or other
entity); concerns about the appropriate oversight mechanism
to employ (e.g., what constitutes human subjects research);
and confidentiality of the genetic, medical, or other information
associated with the cell lines.
Transfer and Sharing of Materials
Sharing of materials and data is crucial for the efficient progress
of stem cell research and clinical translation. Several efforts have
been directed at promoting the registration of, banking of, and
access to stem cell lines and providing associated data, in
particular for human embryonic stem cell (hESC) and induced
pluripotent stem cell (iPSC) lines (Crook et al., 2010; Borstlap
et al., 2010). An emphasis on clinical applications is increasing;
for example, the Center for iPS Cell Research and Application
(CiRA) at Kyoto University plans to establish a clinical grade,
HLA-matched iPSC bank for clinical translation (Cyranoski,
2012). However, a number of barriers may hinder sharing, as
outlined by Kazuto Kato and commentators. While sharing of
materials promises to increase efficiency and the value of
scientific endeavors, there is a lack of incentives in the system
to encourage sharing, ranging from typical practices for publica-
tions to promotion and tenure, grants, and commercialization.
Accordingly, thought should be given to developing appropriate
incentives to overcome these barriers. In addition, securing
funding for banks and databases is challenging because these
activities do not generally make profits.
Other barriers include how to explain the use and transfer of
cells and data at the time of informed consent, how to deal
with the issue of communicating research results to donors,
and how to protect the privacy of donors. In addition, the myriad
of mechanisms to approve translational research remain
confusing and burdensome, especially when the research is
being conducted across cultural and international borders.Cell Stem Cell 11, 765–767, December 7, 2012 ª2012 ISSCR 765
Table 1. Ethical and Policy Issues in the Clinical Translation of Stem Cells: Session Overview
Speakers Commentators
Introductory remarks Jeremy Sugarman, Kazuto Kato
Preclinical barriers: preclinical data Jason Robert Mahendra Rao, Shinji Miyake
Preclinical barriers: transfer and sharing of materials Kazuto Kato Kirstin Matthews
Clinical barriers: trial design and comparators Jonathan Kimmelman Peter Coffey
Clinical barriers: perception and communication of risk:
patients, families, and patient groups
Douglas A. Sipp
Group discussion
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ISSCR: Committee ForumAmong these, the issue of privacy needs special attention, since
stem cells such as iPSCs carry complete genomes of the donors.
The stem cell field might look to human genome research, where
systems have been developed for the protection of personal
data while encouraging data sharing. For example, in an
approach used by several large databases such as the database
of Genotypes and Phenotypes (dbGaP) in the USA and the
International Cancer Genome Consortium (ICGC), genomic
data of individuals are shared with qualified researchers after
strict review (controlled access) but data that do not lead to
identification of individuals, such as aggregated somatic muta-
tion data of cancer tissues, are freely available (Mailman et al.,
2007; ICGC, 2010).
Trial Design and Comparators
Many therapeutic applications of stem-cell-based interventions
involve surgical delivery. However, surgical procedures are
associated with large placebo responses, observer bias, and
effects on tissues that can mimic disease responses. Rigorous
evaluation of stem cell interventions for safety and efficacy
therefore requires randomized trials involving sham compara-
tors. Jonathan Kimmelman suggested that such designs present
at least two ethical challenges. First, they involve a relatively
invasive form of belief manipulation, in which the investigator
enacts a ‘‘theater of surgery.’’ Second, they involve harmwithout
direct benefit. Kimmelman argued that the ethical evaluation of
sham comparator studies should begin by dividing sham risks
into two components: the withholding of care (if any), and the
performance of research procedures that have no compensatory
direct benefit to the patient-subject. The former is justified
provided conditions of clinical equipoise are met (Freedman,
1987). The latter becomes justified through a two-step process
in which risk is minimized given the research objectives, and
then the remaining risk is justified by an appeal to knowledge
value. Looking forward, Kimmelman suggested that researchers
should apply the following six practices when designing
studies involving sham comparators: (1) use the term ‘‘sham’’
or ‘‘invasive placebo’’ rather than comparably benign language
of ‘‘placebo’’; (2) justify the selection of particular sham pro-
cedures; (3) justify the allocation ratio; (4) power studies
adequately; (5) take additional measures to maintain blind, and
test whether blind was maintained after the last endpoint; and
(6) actively report sham-related adverse events.
Commentators highlighted the strong determination of those
seeking experimental interventions. At a personal level, while
the desire for access to new interventions for patients who do
not have good available alternatives is completely understand-766 Cell Stem Cell 11, 765–767, December 7, 2012 ª2012 ISSCRable, there is great concern that using such interventions either
prematurely because of the need for additional scientific devel-
opment or outside of a controlled research setting may cause
unnecessary harm. Further, while early human trials with those
with end-stage disease is commonplace in oncology, it is still
unclear whether this will be the right model for stem cell inter-
ventions because their biological properties as well as the
comorbidities associated with end-stage disease may confound
our understanding of safety and efficacy.
Perception and Communication of Risk: Patients,
Families, and Patient Groups
The communication of risks in stem cell clinical research should
be informed generally by the existing framework and practices
established for human subject research in general but must
also reflect the specific biological characteristics and behaviors
of stem cells. Douglas Sipp pointed out that the properties that
make various forms of stem cells potentially therapeutically
valuable (such as proliferation, differentiation, migration/homing,
and paracrine activity) could also make them harmful. For inves-
tigational protocols that propose to introduce stem cells or their
derivatives such that they achieve lifelong functional integration
into host tissue, the study design must reflect the potential
consequences of studying a biological ‘‘drug’’ that is not ex-
pected to be metabolized or excreted by the body. This has
profound implications for recruitment, informed consent, the
ability of human subjects to completely withdraw from a study
given that it may be impossible to remove the investigational
product, and evaluation of safety, which may not become
apparent for decades. Given the current atmosphere of hope,
expectation, and optimism surrounding the therapeutic potential
of stem cells, special care must also be taken to create realistic
expectations of benefit, as patients may confuse stem cell clin-
ical trials for treatments (Scott et al., 2010). Investigators need
to exercise great caution in distinguishing stem cell clinical
research intended to produce generalizable knowledge from
treatment activities intended primarily for patient care.
Several audience members sought opinion about the ethi-
cality, acceptability, and implications of clinical business
models where human research subjects are asked or required
to pay to participate in clinical research, such as whether, for
example, this raises expectation of a positive medical outcome.
This issue seemed to be especially important in lower income
countries where research funding may be limited. Additional
systematic information about this emerging practice needs to
be gathered and then considered from legal, ethical, and scien-
tific perspectives.
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Throughout the presentations and discussion, the tight relation-
ship between science and ethics was clear, with ethical ques-
tions being coupled tightly to scientific questions. For example,
the ethical and scientific issues of the use of animal models and
their reliability and validity in predicting efficacy and safety work
in tandem. Similarly, the selection of comparators in human
trials raises questions about scientific objectives and validity.
Addressing these issues together in the earliest possible
stages of clinical translation promises to enhance not only the
scientific and ethical quality of the research but also its effi-
ciency. Moving forward will require identifying and describing
models of how the scientific and ethical issues can be ad-
dressed concurrently during research design and oversight so
that they can be disseminated and employed. The issues iden-
tified in this session provide a springboard for future scholarly
work and policy development.
ACKNOWLEDGMENTS
We are deeply appreciative of the time and insights offered by each of the
formal Commentators during the Focus Session: Mahendra Rao (National
Institutes of Health, USA); Shinji Miyake (Pharmaceutical and Medical Devices
Agency, Japan); KirstinMatthews (James A. Baker III Institute for Public Policy,
Rice University, USA); and Peter Coffey (University College London, UK). Inaddition, we benefitted from the questions and comments offered by many
of the participants.REFERENCES
Borstlap, J., Luong, M.X., Rooke, H.M., Aran, B., Damaschun, A., Elstner, A.,
Smith, K.P., Stein, G.S., and Veiga, A. (2010). In Vitro Cell. Dev. Biol. Anim.
46, 242–246.
Crook, J.M., Hei, D., and Stacey, G. (2010). In Vitro Cell. Dev. Biol. Anim. 46,
169–172.
Cyranoski, D. (2012). Nature 488, 139.
Freedman, B. (1987). N. Engl. J. Med. 317, 141–145.
International CancerGenomeConsortium (ICGC), Hudson, T.J., Anderson,W.,
Artez, A., Barker, A.D., Bell, C., Bernabe´, R.R., Bhan, M.K., Calvo, F., Eerola, I.,
Gerhard, D.S., et al. (2010). Nature 464, 993–998.
International Society for Stem Cell Research (2008). The Guidelines for the
Clinical Translation of Stem Cells. http://www.isscr.org/clinical_trans/pdfs/
ISSCRGLClinicalTrans.pdf. Accessed November 8, 2012.
Mailman, M.D., Feolo, M., Jin, Y., Kimura, M., Tryka, K., Bagoutdinov, R., Hao,
L., Kiang, A., Paschall, J., Phan, L., et al. (2007). Nat. Genet. 39, 1181–1186.
Robert, J.S. (2008). Philos. Psychol. 21, 425–436.
Scott, C.T., DeRouen, M.C., and Crawley, L.M. (2010). AJOB Primary Res. 1,
4–11.Kazuto Kato,1,2,* Jonathan Kimmelman,3 Jason Robert,4
Douglas Sipp,5 and Jeremy Sugarman6,*
1Department of Biomedical Ethics and Public Policy, Graduate
School of Medicine, Osaka University, 2-2 Yamadaoka,
Suita 565-0871, Japan
2Institute for Integrated Cell-Material Sciences, Kyoto University,
Ushinomiya-cho, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan
3Biomedical Ethics Unit, McGill University, 3647 Peel Street,
Montreal, QC H3A1X1, Canada
4Center for Biology & Society and School of Life Sciences,
Arizona State University, PO Box 874701, Tempe, AZ 85287, USA
5RIKEN Center for Developmental Biology, 2-2-3 Minatojima
Minamimachi, Chuo-ku, Kobe 650-0047, Japan
6Berman Institute of Bioethics and Department of Medicine,
Johns Hopkins University, 1809 Ashland Avenue, Baltimore,
MD 21205, USA
*Correspondences: katok@eth.med.osaka-u.ac.jp (K.K.),
jsugarman@jhu.edu (J.S.)
http://dx.doi.org/ 10.1016/j.stem.2012.11.004Cell Stem Cell 11, 765–767, December 7, 2012 ª2012 ISSCR 767
